---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-008897"
form_type: "8-K"
ticker: "MAIA"
cik: "0001878313"
company_name: "MAIA Biotechnology, Inc."
filed_at: "2026-03-04T23:59:59+00:00"
generated_at: "2026-05-15T21:50:16.815713+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MAIA Biotechnology closes $30M public offering of 20M shares at $1.50/sh

## Summary
- Closed underwritten public offering of 20M shares at $1.50/sh, gross proceeds $30M.
- Underwriters granted 30-day option to buy up to 3M additional shares for over-allotments.
- Net proceeds to fund clinical trials and working capital; offering closed March 4, 2026.
- Konik Capital Partners acted as sole book-running manager; 60-day lock-up for insiders.
- Offering structured as common stock only with no warrant coverage; led by healthcare investors.

## SEC filing metadata
- accession: 0001493152-26-008897
- form_type: 8-K
- ticker: MAIA
- cik: 0001878313
- company_name: MAIA Biotechnology, Inc.
- filed_at: 2026-03-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1878313/000149315226008897/0001493152-26-008897-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1878313/000149315226008897/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-008897
- JSON: https://secwatch.observer/filing/0001493152-26-008897.json
- Plain text: https://secwatch.observer/filing/0001493152-26-008897.txt

## Key facts
- Material Agreements
  MAIA Biotechnology, Inc. entered into Underwriting Agreement with Konik Capital Partners, LLC, a division of T.R. Winston and Company, LLC valued at approximately $30.0 million (effective 2026-03-02).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Konik Capital Partners, LLC, a division of T.R. Winston and Company, LLC
  - Value: approximately $30.0 million
  - Effective: 2026-03-02
  source text: On March 2, 2026, MAIA Biotechnology, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Konik Capital Partners, LLC, a division of T.R. Winston and Company, LLC (the “Underwriter”), pursuant to which the Company agreed to issue and sell in an underwritten public offering (the “Offering”) an aggregate of 20,000,000 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1878313/000149315226008897/0001493152-26-008897-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.